Matthew Merkley

Matthew Merkley serves as Sr. Director at Atomwise since December 2022, following a tenure as Associate Director of Program Management at Bolt Biotherapeutics, Inc., where responsibilities included overseeing the BDC-2034 program’s IND and engaging with the FDA for timely submission. Prior experience includes pivotal roles at Gilead Sciences as Senior Project Manager and Clinical Pharmacology Project Manager, contributing to global regulatory filings for key products like Veklury and Biktarvy, and managing clinical pharmacology activities. Matthew's career began in research roles, including a Research Assistant position at Gilead and clinical research roles at various institutions. Educational credentials include an MA in Medical Science from Boston University School of Medicine and a Bachelor of Science in Biochemistry/Molecular Biology from the University of California, Davis.